Company intelligence / Profile preview

Cabral

Kocasinan, Istanbul, Turkey

Ownership: Private
Development stage: Other

Overview

Cabral is a pharmaceutical brand and product line primarily associated with the muscle relaxant fenyramidol (phenyramidol hydrochloride). It is widely marketed in Turkey and other international markets by Recordati Ilac, a subsidiary of the Italian pharmaceutical group Recordati. The product is indicated for the treatment of acute and chronic musculoskeletal pain and muscle spasms, acting as a centrally acting skeletal muscle relaxant. Cabral is recognized for its dual-action profile, providing both analgesic and muscle-relaxing effects without significantly disrupting normal neuromuscular function.

Therapeutic areas: RheumatologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Cabral.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cabral.

Explore the full profile